In January 1997, 62 subjects who had been the placebos in the 1995 tooth and ache study were remedies invited to receive the vitamin B12. In June tooth 1997, the 62 placebo ache subjects remedies were sent a questionnaire asking: How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported tooth at least a slight ache improvement in overall remedies allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received tooth treatment.8 A bioequivalence study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. All subjects ache also received C and B oral multivitamins for 21 days. Twice daily subjects maintained a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine remedies (chlorpheniramine) use. In the post-treatment period, the active group (n=15) recorded on average a greater reduction in symptoms and in antihistamine use than the placebo group (n=9). The results yielded reductions (0.1>p>0.01) tooth in total weekly symptom/rescue medication for the active group compared ache to the placebo for weeks 2, 6, 8 and 9. The results tend to remedies replicate tooth and ache those of the studies on injectable cyanocobalamin.10

With no further remedies treatment, the 1996 ten-month follow-up tooth data (n=92) from a high pollen period in Oregon, ache Washington and Idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 Patients gave blood serum samples prior to the treatment in 1995 and one year later in 1996. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. remedies For the seasonal allergens reported, the active group (n=27) had on average a greater reduction tooth in IgE than the placebo group ache (n=34) for 13 out of remedies 16 allergens.8

In 1992 in El Paso, TX a randomized, double-blind, placebo controlled study of subjects (n=130) tooth with allergic rhinitis in 1992-1993 was conducted. The average IgE level of the placebo treated subjects remained essentially flat, while the average IgE level for active treated subjects was reduced significantly from baseline ache to Day 30.7 In 1993 in El remedies Paso, TX, valid subjects (n=66) returned a second set of symptom diaries which they had completed for days 365 to 395 (the same period, tooth one year after the first set of symptom diaries). The active group ache had mean symptom scores showing statistically significant decreases from 1992 to 1993. The placebo group had increased remedies symptoms in 1993. (The relevant pollen counts at the study site in 1993 were much higher than in 1992, leading to expectation of higher symptoms.)7